COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Hip Fracture Surgery and Oral Nutritional Supplements (HIATUS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01505985
Recruitment Status : Terminated
First Posted : January 9, 2012
Last Update Posted : November 25, 2013
Information provided by (Responsible Party):

Brief Summary:
Senior hip fracture patients are the most vulnerable to malnutrition and protein deficiency. Low protein intake, like vitamin D deficiency, contribute to an increased risk for hip fracture. Notably, several clinical trials with protein supplementation in senior hip fracture patients resulted in fewer deaths, shorter hospital stay, and a higher likelihood of return to independent living. The proposal is to test the effect of an oral nutritional supplement (ONS) which has been designed to meet the specific nutrient needs of senior bone and muscle health. The hypothesis is that this ONS will improve functional recovery after hip fracture (as measured by Short Physical Performance Battery (SPPB)), improve quality of life, improve muscle mass, and- decrease falls and hospital re-admission after hip fracture.

Condition or disease Intervention/treatment Phase
Hip Fracture Dietary Supplement: Oral nutritional Supplement Dietary Supplement: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: Effect of a Nutritional Intervention on Hip Fracture Surgery Recovery
Study Start Date : January 2012
Actual Primary Completion Date : September 2013
Actual Study Completion Date : September 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Specialized Oral Nutritional Supplement Dietary Supplement: Oral nutritional Supplement
Specialized nutritional supplement for seniors

Placebo Comparator: Placebo Dietary Supplement: Placebo
placebo product with no specific nutrients

Primary Outcome Measures :
  1. The Short Physical Performance Battery (SPPB) [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Nutritional status [ Time Frame: 6 months ]
  2. Quality of Life [ Time Frame: 6 months ]
  3. Muscle strength [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   70 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age (70+);
  • Had an acute hip fracture and surgical treatment
  • Able to walk at least 3 meters without assistance of another person, with or without a walking aid other than a wheeled walker prior to hip fracture MMSE >=18 (proxy will be informed in addition if MMS-score ≤ 24)
  • Able to perform the SPPB at baseline
  • No prior hip fracture
  • Patient (and/or his/her legal representatives/relatives) understands the study procedure, alternative treatments available and risks involved with the study, and voluntarily agrees to participate by giving his/her (or his/her legal representative's/relatives) written informed consent.

Exclusion Criteria:

  • Baseline visit can not be performed between the second and tenth postoperative day.
  • Milk protein allergy
  • Patients with conservative treatment for hip fracture
  • Serum calcium adjusted for albumin of > 2.6 mmol/L
  • Pathologic fracture in the last year (except for fractures due to osteoporosis)
  • Chemo therapy / Radiation /antihormonal therapy due to cancer in the last year
  • Treatment which has an effect on calcium metabolism (e.g. PTH, calcitonin, chronic cortisone intake > 5mg/day in the last 12 months (except for inhalation and sporadic infiltration))
  • Oral vitamin D intake of more than 1000 IU per day during the last 3 months before the study
  • Unwilling to stop multi-vitamin, calcium supplementation, and vitamin D supplementation during the trial (maximal calcium supplement intake 250mg/d; no additional vitamin D supplementation). We will inform the treating physician that we initiated vitamin D supplementation as standard of care.
  • Severe visual or hearing impairment
  • Unwilling or unable to take study medication
  • Diseases with a risk of recurrent falling (e.g. Parkinson's disease/syndrome, Hemiplegia after stroke, symptomatic stenosis of the spinal canal, polyneuropathy, epilepsy, recurring vertigo, recurring syncope) BMI ≥ 40
  • Estimated creatinine clearance < 15 ml/min (estimated Creatinine Clearance cockcroft and Gault)
  • Malabsorption syndrome (celiac diseases, inflammatory bowel disease, hepatic and/or pancreas dysfunction)
  • Diseases that may enhance serum calcium: sarcoidosis, lymphoma, primary hyperparathyroidism
  • Kidney stone in the last 10 years
  • Patient heavily consumes alcohol containing products defined as greater than (>) 3 drinks (beer, wine, or distilled spirits) of alcoholic beverages per day.
  • Patients who are planning a stay in a "sunny" location (e.g. winter sun resort) for more than one month during the trial
  • Medication which has an effect on serum 25-hydroxyvitamin D level (e.g. certain anticonvulsants (e.g. Phenobarbital, Carbamazepin, Phenytoin) M. Paget (Ostitis deformans)
  • Inflammatory arthritis (e.g. rheumatoid arthritis, reiter syndrome, psoriasis arthritis)
  • Uncontrolled metabolic conditions, or psychiatric conditions that might make tolerance or evaluation of the feeding formula difficult
  • Severe acute and/or chronic disease that makes the performance of the study assessments impossible (e.g. severe infection/sepsis, myocardial infarction, heart failure, respiratory failure or renal failure);
  • Patient is taking peripherally acting anti-adiposity drugs (e.g. Xenical®, formoline L112®, (Acomplia®))
  • Patients taking protein supplements (>15g per serving more than once a week) or are unwilling to stop any protein supplements during the trial Participation in a study in the last 6 month, except for studies without drug-application, or any influence of the study-medication can be excluded
  • Patient is unlikely to adhere to the study procedures, to keep appointments, or is planning to relocate during the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01505985

Layout table for location information
University of Zurich,Dept. of Rheumatology and Institute of Physical Medicine,
Zurich, Switzerland, 8091
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Heike Bischoff-Ferrari,, MD, DrPH University of Zurich
Layout table for additonal information
Responsible Party: Nestlé Identifier: NCT01505985    
Other Study ID Numbers: NES1026CLI
First Posted: January 9, 2012    Key Record Dates
Last Update Posted: November 25, 2013
Last Verified: November 2013
Keywords provided by Nestlé:
Hip fracture
Functional recovery
Additional relevant MeSH terms:
Layout table for MeSH terms
Fractures, Bone
Hip Fractures
Wounds and Injuries
Femoral Fractures
Hip Injuries
Leg Injuries